Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 116 of the 118 references it cites were found in a registry or an index; 11 of the 84 sources its claims cite were checked for support.

The gut microbiota and host health: a new clinical frontier

Open access

Abstract

Over the last 10–15 years, our understanding of the composition and functions of the human gut microbiota has increased exponentially. To a large extent, this has been due to new ‘omic’ technologies that have facilitated large-scale analysis of the genetic and metabolic profile of this microbial community, revealing it to be comparable in influence to a new organ in the body and offering the possibility of a new route for therapeutic intervention. Moreover, it might be more accurate to think of it like an immune system: a collection of cells that work in unison with the host and that can promote health but sometimes initiate disease. This review gives an update on the current knowledge in the area of gut disorders, in particular metabolic syndrome and obesity-related disease, liver disease, IBD and colorectal cancer. The potential of manipulating the gut microbiota in these disorders is assessed, with an examination of the latest and most relevant evidence relating to antibiotics, probiotics, prebiotics, polyphenols and faecal microbiota transplantation.

Overview

CoChat Summary

TL;DR

This narrative review updates the role of the gut microbiota in metabolic/obesity-related disease, liver disease, IBD, and colorectal cancer, and assesses microbiota-modulating therapies including antibiotics, probiotics, prebiotics, polyphenols, and faecal microbiota transplantation. It argues the microbiota is a modifiable, host-specific system with therapeutic and diagnostic potential, while noting that human evidence remains limited by confounding, sampling bias, and equivocal trial results.

Key findings

  • The gut microbiota is described as containing “100 times more genes than the host,” with about 160 species in the large intestine of any individual; function appears more conserved across people than species identity, and 10% of daily energy requirements come from colonic fermentation.
  • In obesity/metabolic disease, metagenomic studies identified high versus low microbial gene richness (HGC/LGC); LGC was linked to proinflammatory *Bacteroides* spp and oxidative-stress genes, while HGC had more *F. prausnitzii* and butyrate-production potential. FMT from lean donors to metabolic syndrome patients significantly increased insulin sensitivity, faecal butyrate, microbial diversity, and *Roseburia intestinalis*-related bacteria.
  • In IBD, the most consistent change is reduced Firmicutes; the IBD metagenome contains “25% fewer genes” than healthy gut. A meta-analysis of FMT in IBD found overall clinical remission in 45% (54/119), and 36% when only cohort studies were analysed.
  • In CRC, pathobionts including *Streptococcus gallolyticus*, *Enterococcus faecalis*, *Bacteroides fragilis*, *E. coli*, and *Fusobacterium nucleatum* have been linked with adenomas/CRC; butyrate-producers are reduced, and H₂S is implicated in CRC development.

Methods

  • Narrative review of current knowledge and evidence, not a primary study; it synthesizes large-scale microbiome projects, metagenomic/metatranscriptomic studies, animal models, human observational studies, RCTs, and meta-analyses.
  • The review covers GI and liver diseases—metabolic syndrome/obesity-related disease, NAFLD/alcoholic/autoimmune liver disease, IBD, and CRC—and evaluates microbiota modulation via antibiotics, probiotics, prebiotics, polyphenols, and FMT.
  • No systematic search strategy, inclusion criteria, or formal quality assessment is reported.

Limitations

  • The paper states that most data derive from faecal samples, which do not represent the complete gut picture; the small intestine differs markedly from the colon, and most studies come from North America and Europe, giving a biased view.
  • It states that human probiotic and prebiotic data are equivocal, with poor study design/strain choice and few well-powered prebiotic trials; obesity links are confounded by diet, host genetics, hormones, lifestyle, and BMI limitations.
  • It states that CRC human studies involve small patient numbers, sampling heterogeneity, limited tumour phenotyping, and limited oncological data. Evident from the text: as a narrative review, it lacks systematic methods and formal evidence grading.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/gutjnl-2015-309990

Cites

116 of 116 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Proposed mechanisms of the gut microbiome in colon cancer aetiology.
Figure 1 Proposed mechanisms of the gut microbiome in colon cancer aetiology.CC BY-NC · PubMed Central

Verification

Claims the paper makes

9 Valid · 14 Not valid · 65 Not checked · 31 Own results and interpretations

53 more claims · 1 with their cited sources checked

Create a free account to see all 119 claims and to verify the 73 references still open.

See all claims — free account
  • It may state two separate claims as one. 50
  • Probably not a substantial claim. 17
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Citations

Cites

Show all 118 references

Cited by

See all 2,302

Metadata

Authors
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A., Hirschfield, G. M., Hold, G., Quraishi, M. N., Kinross, J., Smidt, H., Tuohy, K. M., Thomas, L. V., Zoetendal, E. G., & Hart, A.
Affiliations
  • Imperial College London (GB)
  • University of Birmingham (GB)
  • Nutrition and Nutrigenomics Group, Department of Food Quality and Nutrition, Research and Innovation Centre, Trento, Italy
  • TiFN (NL)
  • University of Aberdeen (GB)
  • Wageningen University & Research (NL)
  • Yakult UK Limited, Middlesex, UK
  • St Mark's Hospital (GB)
Corresponding author
Hart, Ailsa
Venue
Gut
Publisher
BMJ
Published
2015-09-02
Volume
65
Issue
2
Pages
330-339
ISSN
  • 0017-5749 (ISSN-L)
  • 1468-3288
OpenAlex
W2129690444
Cited by
2,302
References
118
Citations by year
2026: 126 · 2025: 195 · 2024: 214 · 2023: 224 · 2022: 257 · 2021: 294 · 2020: 258 · 2019: 201 · 2018: 202 · 2017: 209 · 2016: 114 · 2015: 4
FWCI
17.08
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • Gut (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • ORCA Online Research @Cardiff (Cardiff University) (acceptedVersion)
  • Socio-Environmental Systems Modeling (acceptedVersion, cc-by-nc)
  • CINECA IRIS Institutional Research Information System (Fondazione Edmund Mach) (submittedVersion, cc-by-nc)
  • Aberdeen University Research Archive (Aberdeen University) (submittedVersion)
  • HighWire Press Open Archive (submittedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, cc-by-nc)
Funders
  • National Institute for Health and Care Research (NF-SI-0512-10080, ACF-2012-09-007)
  • Academy of Medical Sciences (AMS-SGCL8-Kinross)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Agricultural and Biological Sciences › Food Science › Probiotics and Fermented Foods
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Keywords
gut microbiota, host health, metabolic syndrome, obesity-related comorbidities, liver disease, inflammatory bowel disease, colorectal cancer, microbiome manipulation, antibiotics, probiotics, prebiotics, polyphenols, fecal microbiota transplantation
MeSH terms
Gastrointestinal Microbiome, Animals, Autoimmune Diseases, Bacteria, Colitis, Ulcerative, Crohn Disease, Health Status, Humans, Liver Diseases, Liver Diseases, Alcoholic, Obesity, Inflammatory Bowel Diseases, Pouchitis, Probiotics, Prebiotics, Polyphenols, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The gut microbiota and host health: a new clinical frontier. https://app.cochat.ai/papers/10.1136/gutjnl-2015-309990
The paper
Marchesi, J. R., Adams, D. H., Fava, F., Hermes, G. D. A., Hirschfield, G. M., Hold, G., Quraishi, M. N., Kinross, J., Smidt, H., Tuohy, K. M., Thomas, L. V., Zoetendal, E. G., & Hart, A. (2016). The gut microbiota and host health: a new clinical frontier. Gut. https://doi.org/10.1136/gutjnl-2015-309990

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.